SAVA Q3 2024 Earnings — Cassava Sciences, Inc. Revenue & Financial Results | Market Cap Arena

SAVACassava Sciences, Inc.

$116M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$18M

Operating Income

-$31M

Net Income

-$28M

EPS (Diluted)

$-0.58

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$224M

Total Liabilities

$57M

Stockholders' Equity

$167M

Cash & Equivalents

$149M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$18M	-$24M	+25.1%
Operating Income	-$31M	-$28M	-9.8%
Net Income	-$28M	-$26M	-8.9%